Resources

  • All
  • Blogs
  • Fact Sheets
  • Infographics

Disrupting the Inflammation Process

Abcentra is leveraging cutting-edge science to develop a portfolio of novel antibody therapeutics for serious inflammatory diseases, where new treatments are critically needed. Chronic inflammation is often the underlying cause of several diseases and conditions including; cancers, rheumatoid arthritis, atherosclerosis, and other cardiovascular diseases. Without intervention, the inflammation process has the potential to last extended periods of time.   Chronic inflammation is an immune response and often... Read more »

Targeting oxLDL for Psoriasis Relief

Psoriasis is a common skin condition that speeds up the life cycle of skin cells, however, many people aren’t exactly sure what causes psoriasis. Psoriasis is a unique and chronic disease that often comes and goes. Psoriasis occurs when your immune system or T cells are out of balance or overactive. An overactive immune system sends faulty signals and the T cells mistake... Read more »

Finding Treatments for Aortic Valve Stenosis

Aortic valve stenosis is the most common and most serious valve disease problem affecting more than one million patients in North America each year. Aortic valve stenosis is the narrowing of the exit of the heart’s left ventricle, which reduces or blocks blood flow into the main artery and to the rest of the body. When the blood flow through the aortic valve is reduced or blocked, the heart... Read more »

The New Medical Frontier

Understanding the Mechanism of Disease for Better Care By Bert Liang, M.D., P.h.D. The high cost of health care is not a new discussion. Each day, we are inundated with heartbreaking stories of patients without access to essential therapies due to rising costs or the inability to pay momentous medical bills. As a public, it... Read more »

Targeting Inflammation to Address Rheumatoid Diseases

Abcentra is working on clinical and preclinical programs focused on addressing unmet needs in inflammatory diseases. Inflammation is a primary driver behind many fatal and life-threatening conditions, including many types of rheumatoid diseases. In the remote past, certain types of rheumatoid diseases have fallen under the broad heading of ‘rheumatism.’ Now, there are more than... Read more »

How Orticumab Slows the Inflammation Process

Orticumab is the first and only fully human monoclonal antibody of its kind targeting oxLDL to slow the inflammation process. Oxidized low density lipoprotein (oxLDL) is implicated in common, chronic conditions caused by inflammation such as cardiovascular disease, rheumatological diseases and cancer. Orticumab has received strong scientific support and has been featured in several peer-reviewed... Read more »

Abcentra’s Goal in Treating Accelerated Atherosclerosis 

Scientists from Abcentra recently contributed to a study published in the American Heart Association Journals, which found an increase in cardiovascular risk when key immune cell participation is lost while treating atherosclerosis with immunotherapy. But what is atherosclerosis? Atherosclerosis occurs when substances such as fats, cholesterol, and immune cells build up on a patient’s artery walls,… Read more »

The Relationship Between oxLDL and CVD

Cardiovascular disease (CVD), a condition that is caused by inflammation, is the leading cause of death in the United States. CVD often leads to heart attacks, chest pain (angina), or stroke. Oxidized low-density lipoprotein (oxLDL) is a harmful type of cholesterol the accelerates inflammatory diseases, such as CVD. By targeting oxLDL, Abcentra aims to create... Read more »

Abcentra’s Orticumab Targets Chronic inflammation 

Chronic inflammation can be a primary contributor to many fatal and life-threatening diseases such as cancers, rheumatoid arthritis, atherosclerosis, and other cardiovascular diseases. While inflammation tends to have a negative connotation, inflammation occurs in the body as a defense mechanism or self-protection as a way to begin the healing process when the immune system recognizes… Read more »

Leading the Fight Against Inflammatory Response

Current medication options for the treatment and management of chronic conditions fail to address the underlying cause and often have dangerous side effects. Patients need therapies that treat the root cause: inflammation. Abcentra aims to provide treatment against an inflammatory response without the severe side effects and safety concerns. Treatments are critically needed, as an... Read more »

Cardiovascular Incidents Rise With Immunosuppressive Therapy

Abcentra is leveraging its cutting-edge science, technology and expertise to contribute to studies on inflammation and cardiovascular disease. Most recently, Abcentra executives contributed to a 2019 study published in the American Heart Association Journals, which found that — in ApoE/MHCII double knockout mice with high-cholesterol and major histocompatibility complex class II (MHCII) deficiency —atherosclerosis was... Read more »

Abcentra Working to Fight Cardiovascular Disease

In a 2017 study by the Institute for Health Metrics and Evaluation (IHME), cardiovascular disease was cited as the major cause of mortality among adults aged 35-70 years, and accounted for one-third of deaths throughout the world. Abcentra is committed to bringing the latest breakthroughs in inflammation therapy to patients with serious inflammatory diseases, which… Read more »

Fighting Systemic Inflammatory Disease

Therapies that target and treat systemic inflammatory disease are important tools in the fight against conditions such as psoriasis and rheumatoid disease. However, traditional therapies are limited in reach and may cause severe side effects that can often lead to a lower quality of life, such as infections, cancer and death. Unfortunately, many current medications… Read more »

Inflammatory Disease: Leading the Fight In Treatment

Inflammation is a primary driver behind many fatal and life-threatening diseases. By targeting inflammation, Abcentra hopes to alleviate symptoms and treat underlying disease, creating a fuller life for patients. Abcentra is developing a novel solution to treat critical diseases for which no current treatment options exist, saving patient lives.

Abcentra: Better Solutions, Better Results

Some of the most chronic and difficult-to-treat conditions in the United States are caused by inflammation — an immune response by the body to a stressor. Conditions like plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis affect millions of patients each year, however, these life-threatening and fatal diseases lack effective treatment options. Without a suitable… Read more »